Both TNF-α and NF-κb can both be targets for future cancer therapies; TNF-α can be triggered to induce apoptosis, and NF-κb can be inhibited to prevent tumour growth and spread, as well as aid in making solid tumour cells more susceptible to apoptosis by treatment with other therapeutic cancer agents. This evidence concerns the gene NFKB1 and cancer.